Answers are grounded in this paper and cite their sources.
Merkel cell carcinoma (MCC) is an aggressive form of skin cancer which, while chemosensitive, has high rates of relapse and chemoresistance, limiting the impact of chemotherapy. An immunogenic tumor, the management of advanced MCC has changed dramatically with the introduction of checkpoint inhibitors. This review will focus on the impact of immunotherapy in unresectable and metastatic MCC, ongoing research in the adjuvant and neoadjuvant settings, and future directions of immune-based strategies for this challenging cancer.
No takes yet. Share an insight, caveat, or question.
Angeles et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: